Molecular diagnosis is performed at the gene level with nucleic acids as the object for detection, with high sensitivity and accuracy.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

The deal comprises Expedeon's core proteomics business, as well as its immunology-focused subsidiaries Innova Biosciences and TGR Biosciences. Following the transaction, Expedeon said it will change its name and focus on its genomics operati

Epigenetics research and sample preparation service provider Diagenode announced Tuesday that it has partnered with Bio-Rad Laboratories to offer its single-cell transposase accessible chromatin by sequencing (ATAC-seq) services on Bio-Rad's

Becton Dickinson said on Tuesday that it has submitted a premarket approval (PMA) supplement to the US Food and Drug Administration for an expanded version of its Onclarity human papilloma virus (HPV) assay.

Beckman Coulter Life Sciences and IncellDx said today that they have partnered to promote in Europe four newly developed cancer assays that incorporate technology from each company.

Becton Dickinson is advising its shareholders to reject an unsolicited mini-tender offer they may have received to sell their shares of the company's stock.

Australian molecular diagnostics firm Genetic Signatures has raised $25 million, it said recently.

A consortium led by private equity firms Cinven and Astorg said recently that it has signed an agreement to acquire life science tools company LGC for an undisclosed amount, subject to regulatory approval and other customary clearances.

British life science reagents and tools company Abcam said recently that it has signed an agreement to use BrickBio's proprietary bioconjugation platform to develop research and diagnostic products.

Invitae said recently that it will acquire Clear Genetics, a developer of software that supports the delivery of genetics services at scale, for approximately $50 million.

Expedeon announced recently that it has agreed to sell its immunology and proteomics businesses to UK-based life science reagents and tools company Abcam for €120 million ($130.0 million) in cash.